RedHill teams with Mayo Clinic, MD Anderson on new cancer trial

Tel-Aviv, Israel-based RedHill Biopharma (Nasdaq: RDHL) – which is continuing to build up its U.S. commercial operations based in Raleigh – is teaming with the Mayo Clinic and The University of Texas MD Anderson Cancer Center on a new cancer trial. The new Phase IIa study is for YELIVA – a product candidate RedHill acquired from Apogee Biotechnolo gy back in 2015 – for the treatment of cholangiocarcinoma, or bile duct cancer. It will enroll patients at Mayo Clinic campuses in both Arizona…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news